To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Butylscopolamine
Butylscopolamine, also known as scopolamine butylbromide and hyoscine butylbromide is an anticholinergic agent[1] used as an abdominal-specific antispasmodic. It is marketed under the trade name Buscopan by Boehringer Ingelheim GmbH, Germany, who also offer a combination of butylscopolamine and acetaminophen, marketed under the name Buscopan Plus. Additional recommended knowledgeButylscopolamine is used to treat pain and discomfort caused by abdominal cramps or other spasmodic activity in the digestive system. When taken orally, it cannot enter the bloodstream or otherwise leave the digestive tract, so that it is only able to affect the smooth muscles of the digestive system as it passes through. It is not an analgesic in the normal sense, since it doesn't 'mask' or 'cover over' the pain, but rather works to prevent painful cramps and spasms from occurring in the first place. UsageButylscopolamine is often prescribed at a low dosage, commonly 10mg three times a day, as a means of managing some of the symptoms of Irritable bowel syndrome. References
|
||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Butylscopolamine". A list of authors is available in Wikipedia. |
- LDC and Roche will jointly advance innovative drug discovery projects - LDC Enters new Industry Partnership for the Discovery of Novel Medicines
- Scientists identify genes that control smooth muscle contraction
- Online Microscopy Platform: See-through for Everyone! - One can focus through the high-resolution specimens just like on a microscope, in order to see details in sharp focus that are located in different layers
- Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG - Noel Barrett appointed as additional member of the supervisory board
- SORCUS Computer GmbH - Heidelberg, Deutschland